Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

Breast Cancer Research

Table 1 Patient characteristics

	Patients retaining trastuzumab		Patients halting trastuzumab
	Percentage	Number 59	Percentage	Number 23
Age in years, mean (range)^a	51 (26–74)		58 (36–77)
<50 years	41	24	22	5
≥ 50 years	59	35	78	18
Oestrogen receptor/Progesterone receptor
+/+	49	29	43	10
+/-	10	6	9	2
-/-	39	23	39	9
Unknown	2	1	9	2
Node
Negative	12	7	13	3
Positive	66	39	52	12
Unknown	22	13	35	8
Grade
1–2	10	6	26	6
3	54	32	43	10
Unknown	36	21	31	7
Adjuvant Therapy
Anthracycline	44	26	31	7
Anthracycline/taxane	10	6	13	3
No anthracycline/taxane	46	27	56	13
HER2
2+^b	12	7	9	2
3+	56	33	48	11
Other (positive)^c	32	19	43	10
Site of disease before trastuzumab therapy^d
1 site	59	35	78	18
≥ 2 sites	41	24	22	5
Bone		23		5
Liver		14		7
Lung		15		7
Nodes		9		2
Skin		9		4
Other		13		3

^aAge at the time when trastuzumab therapy was started. ^bAll 2+ patients had amplification of HER2 gene (fluorescence in situ hybridization-positive). ^cPositive was indicated by a pathologist as intense and diffuse membrane staining in more than 10% of tumor cells. ^dSite information refers to the start of trastuzumab treatment.

ISSN: 1465-542X